Moonsom Seangdeun, Tayapiwatana Chatchai, Wongkham Sopit, Kongtawelert Prachya, Kasinrerk Watchara
Biomedical Technology Research Center, National Center for Genetic Engineering and Biotechnology, National Science and Technology Development Agency at the Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
Hybridoma (Larchmt). 2010 Feb;29(1):45-52. doi: 10.1089/hyb.2009.0096.
CD147/EMMPRIN (extracellular matrix metalloproteinase inducer) is a cell surface glycoprotein that displays increased expression in many cancers. It has been previously demonstrated to participate in cancer metastasis and progression. In this study we used an anti-CD147 monoclonal antibody and a recombinant CD147 protein generated in our laboratory to establish a competitive ELISA for quantifying serum CD147 levels. Unexpectedly, the CD147 level was highest in sera of normal subjects and significantly reduced in sera of cancer patients. There was no significant difference in serum CD147 level between benign, non-metastatic, and metastatic stages of cancers. In regard to liver diseases, the maximal CD147 level was observed in sera of patients with hepatitis and hepatocellular carcinoma, and significantly decreased in patients with liver cirrhosis and cholangiocarcinoma. Our results imply that there may be homeostasis of CD147 levels in sera under normal physiological conditions, while such a level is altered in cancer patients.
CD147/细胞外基质金属蛋白酶诱导因子（EMMPRIN）是一种细胞表面糖蛋白，在许多癌症中表达增加。先前已证明它参与癌症转移和进展。在本研究中，我们使用抗CD147单克隆抗体和在我们实验室中产生的重组CD147蛋白建立了一种竞争性ELISA，用于定量血清CD147水平。出乎意料的是，正常受试者血清中的CD147水平最高，而癌症患者血清中的CD147水平显著降低。癌症的良性、非转移和转移阶段之间的血清CD147水平没有显著差异。关于肝脏疾病，在肝炎和肝细胞癌患者的血清中观察到最大的CD147水平，而在肝硬化和胆管癌患者中显著降低。我们的结果表明，在正常生理条件下，血清中CD147水平可能存在稳态，而在癌症患者中这种水平会发生改变。
